APD-356 (Arena).
Arena is developing APD-356, the lead in a series of orally active, small-molecule 5-hydroxytryptamine 2C agonists for the potential treatment of obesity and diabetes. A phase IIb trial was initiated in June 2005, and preliminary results were expected at the end of 2005.
Jandacek
Ronald J
RJ
The University of Cincinnati, Department of Pathology, Cincinnati, OH 45237, USA. ronald.jandacek@uc.edu
D000818:Animals; D001067:Appetite Depressants / Q000737:chemistry / Q000627:therapeutic use*; D001552:Benzazepines / Q000737:chemistry / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism; D004345:Drug Industry; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000627:therapeutic use*; D009765:Obesity / Q000188:drug therapy* / Q000378:metabolism; D058826:Serotonin 5-HT2 Receptor Agonists; D013329:Structure-Activity Relationship; D016896:Treatment Outcome
D001067:Appetite Depressants; D001552:Benzazepines; D007004:Hypoglycemic Agents; D058826:Serotonin 5-HT2 Receptor Agonists; C506658:lorcaserin